UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: thiopurines in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2006-09, Vol.24 (5), p.715-729

2006

Volltextzugriff (PDF)

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

Alimentary pharmacology & therapeutics, 2018-02, Vol.47 (3), p.356-363

2018

Volltextzugriff (PDF)

Pharmacogenetics of thiopurines in inflammatory bowel disease

Current pharmaceutical design, 2010, Vol.16 (2), p.145-154

2010

Volltextzugriff (PDF)

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype

Alimentary pharmacology & therapeutics, 2017-11, Vol.46 (10), p.953-963

2017

Volltextzugriff (PDF)

The Effect of Renal Replacement Therapy in a Patient with Mercaptopurine Toxicity: Time to Revise Guidelines

Current drug safety, 2024-01, Vol.19 (2), p.299-302

2024

Volltextzugriff (PDF)

A value proposition for trough level-based anti-TNFα drug dosing

Clinica chimica acta, 2019-02, Vol.489, p.89-95

2019

Volltextzugriff (PDF)

Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study

Clinical rheumatology, 2017-09, Vol.36 (9), p.2129-2134

2017

Volltextzugriff (PDF)

Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring

European journal of endocrinology, 2014-12, Vol.171 (6), p.677-683

2014

Volltextzugriff (PDF)

The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients

Alimentary pharmacology & therapeutics, 2005-10, Vol.22 (7), p.605-611

2005

Volltextzugriff (PDF)

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

The pharmacogenomics journal, 2018-01, Vol.18 (1), p.160-166

2018

Volltextzugriff (PDF)

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations

Digestive and liver disease, 2005-04, Vol.37 (4), p.282-297

2005

Volltextzugriff (PDF)

Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants

Acta Paediatrica, 2014-06, Vol.103 (6), p.612-617

2014

Volltextzugriff (PDF)

Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients

Digestive and liver disease, 2008-02, Vol.40 (2), p.108-113

2008

Volltextzugriff (PDF)

Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?

Digestive and liver disease, 2007-02, Vol.39 (2), p.156

2007

Volltextzugriff (PDF)

Safety of thiopurines in the treatment of inflammatory bowel disease

Scandinavian journal of gastroenterology, 2003-01, Vol.38 (239), p.69-72

2003

Volltextzugriff (PDF)

Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease

Digestive and liver disease, 2007-02, Vol.39 (2), p.182-186

2007

Volltextzugriff (PDF)

Extended Thiopurine Metabolite Assessment During 6-Thioguanine Therapy for Immunomodulation in Crohn's Disease

Journal of clinical pharmacology, 2007-02, Vol.47 (2), p.187-191

2007

Volltextzugriff (PDF)

Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients

Gut, 2008-06, Vol.57 (6), p.872-872

2008

Volltextzugriff (PDF)

P451 Early infliximab trough levels in paediatric IBD patients predict sustained remission

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i581-i582

2023

Volltextzugriff (PDF)

P909 Proactive therapeutic drug monitoring and pharmacogenomics in mercaptopurine therapy for ulcerative colitis

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1662-i1663

2024

Volltextzugriff (PDF)

Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy

Clinical drug investigation, 2004-01, Vol.24 (8), p.479-486

2004

Volltextzugriff (PDF)

Non‐detectable levels of 6‐thioguanine nucleotides and 6‐methylmercaptopurine in a patient treated with azathioprine: a case report

British journal of clinical pharmacology, 2007-04, Vol.63 (4), p.508-508

2007

Volltextzugriff (PDF)

P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i529-i529

2022

Volltextzugriff (PDF)

6‐Thioguanine in azathioprine and 6‐mercaptopurine intolerant patients with inflammatory bowel disease

British journal of clinical pharmacology, 2002-05, Vol.53 (5), p.546P-547P

2002

Volltextzugriff (PDF)

DOP035 Early assessment of thiopurine metabolites predicts the occurrence of leukopenia in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S31-S32

2014

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(70)

Sprache

Englisch
(70)

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(56)
Humans
(47)
Female
(26)
Adult
(25)
Male
(25)
Pharmacology & Pharmacy
(25)
Gastroenterology & Hepatology
(22)
Inflammatory Bowel Diseases - Drug Therapy
(22)
Middle Aged
(21)
Inflammatory Bowel Disease
(14)
Aged
(12)
Azathioprine - Adverse Effects
(11)
Mercaptopurine - Adverse Effects
(11)
Netherlands
(11)
Prospective Studies
(11)
6-Mercaptopurine
(9)
Medicine
(9)
Medicine & Public Health
(9)
Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Review article: thiopurines in inflammatory bowel disease

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

Pharmacogenetics of thiopurines in inflammatory bowel disease

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype

The Effect of Renal Replacement Therapy in a Patient with Mercaptopurine Toxicity: Time to Revise Guidelines

A value proposition for trough level-based anti-TNFα drug dosing

Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study

Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring

The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations

Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants

Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients

Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?

Safety of thiopurines in the treatment of inflammatory bowel disease

Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease

Extended Thiopurine Metabolite Assessment During 6-Thioguanine Therapy for Immunomodulation in Crohn's Disease

Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients

P451 Early infliximab trough levels in paediatric IBD patients predict sustained remission

P909 Proactive therapeutic drug monitoring and pharmacogenomics in mercaptopurine therapy for ulcerative colitis

Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy

Non‐detectable levels of 6‐thioguanine nucleotides and 6‐methylmercaptopurine in a patient treated with azathioprine: a case report

P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients

6‐Thioguanine in azathioprine and 6‐mercaptopurine intolerant patients with inflammatory bowel disease

DOP035 Early assessment of thiopurine metabolites predicts the occurrence of leukopenia in inflammatory bowel disease patients

Suchergebnisse filtern